(Stockholm, Sweden, September 29, 2021) Inhalation Sciences AB (ISAB) announces Today, it has commissioned Redeye to regularly, in-depth stock analysis of the company. The strategic goal is to increase ISAB’s market profile and visibility, so that investors and stakeholders can develop a better understanding of the business and its results and future prospects.
Redeye specializes in providing analyzes and insights about companies in the Nordic region’s fast-growing and innovative Life Science and Technology sector. Redeye’s first report on ISAB has now been published and is available on ISAB’s website, https://www.inhalation.se/investors/bolagsanalys/, and on Redeye’s website, www.redeye.se/company/inhalationsciences.
For more information on inhalation sciences, please contact:
Manoush Masarrat, VD
Email: [email protected]
Mobile: +46 (0) 73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Science Sweden AB (publ) develops and commercializes world-leading inhalation research instruments and services. The company’s patented laboratory instruments PreciseInhale® and DissolvIt® enable researchers in the pharmaceutical industry to decide on drug pipeline at an early stage, saving time and resources for R&D departments and enabling researchers at academic institutions to define how aerosols and small particles affects our lungs, and so our health, when we inhale.
(c) 2021 Cision. All rights reserved., Source Press releases – English